204 related articles for article (PubMed ID: 30150444)
1. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
Kogure Y; Shigematsu F; Oki M; Saka H
In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
[TBL] [Abstract][Full Text] [Related]
2. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
3. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
4. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
5. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
Zhou J; Li Y; Zhang Y; Dai H; Guo S
Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
[TBL] [Abstract][Full Text] [Related]
6. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
[TBL] [Abstract][Full Text] [Related]
8. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.
Kawamura T; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Nakajima T; Ohde Y; Endo M; Takahashi T
Cancer Sci; 2016 Jul; 107(7):1001-5. PubMed ID: 27145431
[TBL] [Abstract][Full Text] [Related]
9. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM
Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588
[TBL] [Abstract][Full Text] [Related]
10. Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes.
Ye L; Mesbah Ardakani N; Thomas C; Spilsbury K; Leslie C; Amanuel B; Millward M
Pathol Oncol Res; 2020 Oct; 26(4):2371-2379. PubMed ID: 32506395
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
12. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
[TBL] [Abstract][Full Text] [Related]
13. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients.
Matsuo N; Azuma K; Sakai K; Hattori S; Kawahara A; Ishii H; Tokito T; Kinoshita T; Yamada K; Nishio K; Hoshino T
Sci Rep; 2016 Nov; 6():36458. PubMed ID: 27811988
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.
Peng M; Weng YM; Liu HL; Yang GF; Yao Y; Han G; Song QB
Biomed Res Int; 2018; 2018():7181368. PubMed ID: 29581983
[TBL] [Abstract][Full Text] [Related]
15. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
Takeda Y; Naka G; Yamaguchi Y; Hashimoto M; Suzuki M; Izumi S; Sugiyama H
BMC Cancer; 2020 Oct; 20(1):951. PubMed ID: 33008313
[TBL] [Abstract][Full Text] [Related]
16. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
17. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
[TBL] [Abstract][Full Text] [Related]
18. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
19. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
Sueoka-Aragane N; Katakami N; Satouchi M; Yokota S; Aoe K; Iwanaga K; Otsuka K; Morita S; Kimura S; Negoro S;
Cancer Sci; 2016 Feb; 107(2):162-7. PubMed ID: 26577492
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]